Geron Corporation
Geron develops RYTELO (imetelstat), an oligonucleotide telomerase inhibitor approved in the U.S.
SCHEDULE 13G/AAug 14Latest SEC filing
Aug 6Latest story
August 2026
Sign inSign inGeron develops RYTELO (imetelstat), an oligonucleotide telomerase inhibitor approved in the U.S.